BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kadura S, Raghu G. Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review. Eur Respir Rev 2021;30:210123. [PMID: 34750115 DOI: 10.1183/16000617.0123-2021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Yamaguchi K, Yamaguchi A, Ito M, Wakamatsu I, Itai M, Muto S, Uno S, Aikawa M, Kouno S, Takemura M, Yatomi M, Aoki-Saito H, Koga Y, Hara K, Motegi S, Tsukida M, Ota F, Tsukada Y, Motegi M, Nakasatomi M, Sakairi T, Ikeuchi H, Kaneko Y, Hiromura K, Maeno T. Clinical differences among patients with myeloperoxidase-antineutrophil cytoplasmic antibody-positive interstitial lung disease. Clin Rheumatol 2023;42:479-88. [PMID: 36194347 DOI: 10.1007/s10067-022-06388-5] [Reference Citation Analysis]
2 Wu T, Zhang Y, Cen Z, Ying Y, Sun C, Lv C, Ding Q. Clinical significance of acute exacerbation in interstitial lung disease with antineutrophil cytoplasmic antibody: an indicator of poor prognosis. Ther Adv Respir Dis 2022;16:17534666221140974. [PMID: 36484348 DOI: 10.1177/17534666221140974] [Reference Citation Analysis]
3 Hernández Muñiz S, Olivera Serrano M, Jiménez Heffernan J, Valenzuela C, Caballero Sánchez-robles P. Enfermedad intersticial asociada a conectivopatías y vasculitis. Radiología 2022;64:250-264. [DOI: 10.1016/j.rx.2022.07.003] [Reference Citation Analysis]
4 Montes Ruiz Cabello M, Callejas Rubio JL, García Villanova P. Fibrosis pulmonar idiopática y determinaciones serológicas de autoinmunidad. Medicina Clínica 2022. [DOI: 10.1016/j.medcli.2022.09.018] [Reference Citation Analysis]
5 Bell PT, Sheehy R, Droney L, Prain K, Wong R, Keir GJ. Pulmonary involvement in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis: A single centre case series. Respirol Case Rep 2022;10:e01058. [PMID: 36284753 DOI: 10.1002/rcr2.1058] [Reference Citation Analysis]
6 Sun K, Fisher JH, Pagnoux C. Interstitial Lung Disease in ANCA-Associated Vasculitis: Pathogenic Considerations and Impact for Patients' Outcomes. Curr Rheumatol Rep 2022;24:259-67. [PMID: 35794350 DOI: 10.1007/s11926-022-01078-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Yamakawa H, Toyoda Y, Baba T, Kishaba T, Fukuda T, Takemura T, Kuwano K. Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review. JCM 2022;11:3835. [DOI: 10.3390/jcm11133835] [Reference Citation Analysis]
8 Liossis SC, Bounia CA. Treating Autoimmune-Related Interstitial Lung Disease With B Cell Depletion. Front Med 2022;9:937561. [DOI: 10.3389/fmed.2022.937561] [Reference Citation Analysis]
9 Yoshimura M, Fujieda Y, Sugawara M, Kono M, Kato M, Yokota I, Amengual O, Ito YM, Atsumi T. Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time-averaged DAS28CRP: a nested case-control study. Rheumatol Int 2022. [PMID: 35384451 DOI: 10.1007/s00296-022-05121-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Hozumi H, Kono M, Hasegawa H, Kato S, Inoue Y, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Inui N, Nakamura Y, Yokomura K, Nakamura H, Suda T. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model. Respir Res 2022;23:57. [PMID: 35277175 DOI: 10.1186/s12931-022-01978-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Conticini E, d’Alessandro M, Bergantini L, Castillo D, Cameli P, Frediani B, Cantarini L, Bargagli E. KL-6 in ANCA-Associated Vasculitis Patients with and without ILD: A Machine Learning Approach. Biology 2022;11:94. [DOI: 10.3390/biology11010094] [Reference Citation Analysis]